New Efficacy Results on the use of Cicaplast Baume B5+ in adjunct to Actinic keratosis treatments
New Efficacy Results on the use of Cicaplast Baume B5+ in adjunct to Actinic keratosis treatments According to the latest published actinic keratosis consensus, optimal supportive dermo-care is crucial for patients undergoing treatments like 5-Fluorouracil and Imiquimod. Thus, dermocosmetics shall focus on maintaining skin integrity, minimizing inflammatory reactions, enhancing patient comfort, and ensuring adherence to therapy by reducing severe side effects.
Cicaplast Baume B5+ has been tested in real-life practice in adjunct to 5-Fluorouracil and Imiquimod.
The outcomes below elevate Cicaplast Baume B5+ as a new standard of care for enhancing patient experience and therapeutic success during intensive AK treatments.
CICAPLAST BAUME B5+ STRONGLY REDUCES ALL TESTED AK SKIN SYMPTOMS BOOSTING QUALITY OF LIFE
CICAPLAST BAUME B5+ SUPERIOR PATIENT EXPERIENCE OUTCOMES
CICAPLAST BAUME B5+ HIGH TO EXCELLENT TOLERANCE ASSESSED BY DOCTORS & PATIENTS
REFERENCES
p<0.01
Observational study, Cicaplast Baume B5+ in adjunct to AK treatments, 87 patients with AK, at least once per day as prescribed by the Dermatologist
p<0.01
Observational study, Cicaplast Baume B5+ in adjunct to AK treatments, 87 patients with AK, at least once per day as prescribed by the Dermatologist